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Abstract 
Solubility and drug dissolution are of crucial importance for drug formulations. Poor 
water-solubility of drug candidates is a major obstacle in drug development, since the oral 
route is the most patient convenient and cost effective way to deliver drugs. In some cases 
the low aqueous solubility may limit the bioavailability when the absorption of the drug is 
dissolution limited. About 40% of the current lead optimization compounds suffer from 
poor solubility. 
Improvements in drug solubility/dissolution testing technologies (e.g. high throughput 
screening, HTS) can enhance the possibilities of the lead compounds to success in the later 
stages of drug development process. Typically HTS protocols measure the kinetic 
solubility involving co-solvents (e.g. dimethyl sulfoxide), which might enhance the in 
vitro solubility or give erroneous results if the potential drug candidates are eliminated. 
Also, measurement of dissolution profiles is not available by the present HTS methods. 
For these reasons, there is a need for improvements in HTS solubility formats.  
Traditionally the in vitro dissolution tests are studied by pharmacopoeial methods, 
which are not utilizable in the drug discovery stage because of the large amount of 
compounds needed. However, dissolution studies at the drug discovery stage could be 
useful e.g. to classify compounds based on their dissolution rates. In addition, the initial 
steps of dissolution process might be lost by the regulatory dissolution methods. 
The aim of this thesis was to miniaturize traditional drug dissolution and solubility 
testing methods. Systematic down scaling of methods was done towards the development 
of both equilibrium and kinetic 96-well plate solubility/dissolution methods.  
Miniaturization of the regulatory dissolution methods and shake-flask solubility 
measurements on the 96-well plates was successful. 96-well plate methods for equilibrium 
drug solubilities, as well as for drug dissolution profiles as a function of time, were 
developed. The former method is the first true equilibrium solubility method, which can 
be used in the screening of drug solubility and dissolution phenomena at the early stages 
of drug development process. This method was also tested using fasted state human 
intestinal fluid as a medium for the first time. Human intestinal fluid and data obtained 
might turn out to be important for very low water-solubility compounds. Surface tension 
based microtensiometry was also presented as an alternative method for kinetic HTS of 
drug solubility properties, e.g. for classifying solubility of compounds not suitable for UV-
analysis. Channel flow methodology was introduced enabling especially the kinetic 
follow-up at the very beginning of the dissolution process.    
This thesis provides directly applicable new miniaturized methods for the drug 
solubility and dissolution experiments. These methods enhance the throughput and 
understanding of drug solubility/dissolution phenomena and profiles in drug discovery and 
improve success in the later stages of the drug development process.     
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1 Introduction 
Oral route is the most patient convenient and cost effective way to deliver drugs. 
However, inadequate aqueous solubility and dissolution in intestines and colon limits the 
bioavailability of drugs. Nowadays even 40% of the lead optimization compounds are 
poorly water-soluble (Lipinski et al., 1997). Although the poor solubility can be 
occasionally overcome by novel formulations, e.g. oral lipid-based (Porter and Charman, 
2001; Hauss, 2007) or amorphous formulations (Kawakami 2009), or delivery systems, 
e.g. cyclodextrins (Szejtli, 1988; Brewster and Loftsson, 2007), it still increases the cost 
and time of the new drug product to enter the market. Instead, improvement of drug 
solubility/dissolution testing methods (e.g. by high throughput screening, HTS) in the drug 
discovery stage can enhance the possibilities of the lead compound to success in the later 
stages of the drug development process.         
HTS solubility methods measure the solubility of numerous compounds at small 
quantities (Pan et al., 2001; Chen et al., 2002b; Takano et al., 2006; Bard et al., 2008; Dai 
et al., 2008; Alelyunas et al., 2009). Discovery protocols typically measure the kinetic 
solubility involving small amounts of co-solvents like dimethyl sulfoxide (DMSO). The 
co-solvents might enhance the in vitro solubility due to the co-solvent effect (Chen et al., 
2002b) and the solubility in vivo might be totally different. Especially, for the poorly 
soluble drugs the solubility can increase manifold with co-solvents. Also, erroneous 
decisions can be made if wrong drug candidates are eliminated because of rapid uptake of 
water by DMSO. When the water concentration in the DMSO solution gets too high, some 
lead compounds may fall out of solution and give a false negative result (Homon and 
Nelson, 2006). For these reasons, there is a need for improvements in HTS solubility 
formats.   
Drug dissolution testing of solid dosage forms is a routine process in pharmaceutical 
industry to evaluate drug release characteristics and to predict in vivo behavior. 
Traditionally the in vitro dissolution tests are studied by pharmacopoeial methods (e.g. 
paddle and basket methods) in the product development process for quality control, e.g. to 
assess the lot-to-lot quality and to detect changes in the drug formulation or manufacturing 
process. In the development of the drug product dissolution tests have been used to study 
the excipients (Omelczuk and McGinity, 1993; Uesu et al., 2000), and also to determine 
bioequivalence. In the drug discovery process pharmacopoeial dissolution methods are not 
utilizable because of the large amount of lead compounds and/or drug candidates needed, 
however, dissolution studies at the drug discovery stage could be used to e.g. to classify 
compounds based on their dissolution rates or to show whether the dissolution has taken 
place.  
Biopharmaceutics Classification System (BCS), which divides drugs into four classes 
according to their solubility and permeability properties, correlates in vitro drug product 
dissolution and in vivo bioavailability (Amidon et al., 1995). After BCS the meaning and 
application of relevant solubility/dissolution media has become more important and a 
broad range of dissolution media have been developed, e.g. FaSSIF (fasted state simulated 
intestinal fluid) and FeSSIF (fed state simulated intestinal fluid) (Galia et al., 1998). Still, 
the most physiological medium for solubility and dissolution studies would be human 
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intestinal fluid (HIF), because drugs are usually dissolved and absorbed in the small 
intestine. The miniaturized drug solubility and dissolution methods requested above 
should enable the use of HIF when appropiate.  
In this thesis, different approaches were studied to miniaturize solubility and 
dissolution testing methods. The in vitro in vivo (IVIV) correlation of the solubility testing 
was studied by using different buffer solutions and fasted state human intestinal fluid as 
media. The literature review focuses on the different available solubility and dissolution 
methods and on the IVIV correlation. 
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2 Review of the literature 
2.1 Solubility in drug discovery and development  
IUPAC (The International Union of Pure and Applied Chemistry) defines solubility as 
‘the analytical composition of a mixture or solution which is saturated with one of the 
components of the mixture or solution, expressed in terms of the proportion of the 
designated component in the designated mixture or solution’ (Lorimer and Cohen-Adad, 
2003). Solubility can further be defined in a more specific manner, like unbuffered, 
buffered and intrinsic solubility. Unbuffered solubility means the solubility of a saturated 
solution of the compound at the final pH of the solution. Buffered (apparent) solubility 
refers to solubility at a given pH, measured in a defined pH-buffered system, and usually 
does not perceive the influence of salt formation with counterions of the buffering system 
on the measured solubility value. Intrinsic solubility (So) is the solubility of the neutral 
form of an ionizable compound. For neutral compounds all three definitions coincidence. 
Solubility measurements determine either kinetic or equilibrium (thermodynamic) 
solubility depending on the experimental set-up (Alsenz and Kansy, 2007).  
Compounds can be divided into highly or poorly soluble ones. Traditionally 
compounds were considered to be poorly soluble if the solubility was less than 100 μg/ml. 
In 2006 Fligge and Schuler redefined the concept of poor solubility by HTS method; a 
compound is poorly soluble when the solubility is less than 20 μg/ml, partly soluble when 
the solubility is 20-80 μg/ml and soluble when the solubility is over 80 μg/ml. According 
to Lipinski (2004), 15% of the drug-like compounds and 40% of lead optimization 
compounds were insoluble at a concentration of less than or equal to 20 μg/ml. The 
definitions of drug-likeness and lead-likeness have been discussed e.g. by Oprea et al. 
(2001), but in general it can be said that in the lead optimization process a lead compound 
is moved towards a drug candidate having drug-like properties. In the pharmacopoeias 
solubility is indicated by the descriptive terms (Table 1). 
Table 1.  The descriptive terms for the solubility used in the pharmacopoeias (USP, 
2009;Ph.Eur., 2009). 
Term Parts of solvent required for 1 part of solute 
Very soluble 
Freely soluble 
Soluble 
Sparingly soluble 
Slightly soluble 
Very slightly soluble 
Practically insoluble, or insoluble 
Less than 1 
From 1 to 10 
From 10 to 30 
From 30 to 100 
From 100 to 1000 
From 1000 to 10 000 
Greater than or equal to 10 000  
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The requirement to the drug candidate’s solubility has been studied by the concept of 
maximum absorbable dose (MAD) (Johnson and Swindell, 1996): 
 
MAD = S6.5 VL kat       (1) 
 
The unit of MAD is milligram, the transit time, t, is 270 minutes and the estimated luminal 
volume, VL, is 250 ml. S6.5 marks the solubility at pH 6.5 (mg/ml) and ka the 
transintestinal absorption rate constant (min-1). In the MAD equation the small intestine 
can be considered as a tube, which has the volume of 250 ml. The saturated drug 
suspension is set into that tube, and the timer is started. The absorption rate constant 
describes how fast the dissolved quantity of the drug ‘leaks’ out of the tube each minute. 
After 270 minutes the total amount of ‘leakage’ is the estimate of the amount of the drug 
that should be intestinally absorbed. If that estimated quantity is close to the entire drug 
dosage, the intestinal absorption should be 100%.  
Lipinski (2000) has developed further the MAD concept based on the most common 
clinical potency of drug dose, 1 mg/kg. According to Lipinski, in the case of permeability 
being the average, the equilibrium (thermodynamic) solubility should be 52 μg/ml at pH 
6.5-7. For the low permeability drugs the equilibrium solubility should be 207 μg/ml and 
for the high permeability drugs 10 μg/ml, in order to be therapeutically effective. Low 
dose drugs (0.1 mg/kg) with high permeability can be effective even at the equilibrium 
solubility of 1 μg/ml and, on the opposite cases, 10 mg/kg dose drugs having low 
permeability properties might need equilibrium solubilities of as high as 2100 μg/ml to be 
effective. The advantage of the MAD model is that it easily shows the impact that the 
required dose might have to the permeability, solubility and fraction absorbed of the dosed 
compound.      
The solubility determinations are performed several times along the drug discovery 
and development processes, only varying the focus, the amount of the drug used and also 
the level of the purity and crystallinity of the drug candidate. In the early drug discovery 
stage the goal is to rank compounds according to the solubility and to aid in the structure 
activity chemistry relationships; in the drug development stage the goal is a more accurate 
numerical solubility number (Lipinski, 2004). More precisely, during the lead 
identification the solubility assays are, e.g., used to recognize compounds with potential 
liabilities, while in the lead optimization solubility information is used to make informed 
decisions on potential development candidates. Also the equilibrium solubility is used to 
confirm earlier kinetic solubility results in the lead optimization. In the drug development 
stage the dissolution testing is an important area for solubility assays (Dokoumetzidis and 
Macheras, 2006). In the earlier drug development stages the goal is, e.g., to identify rate-
limiting steps, while in the later stages the dissolution tests are used, e.g., in the quality 
control and bioequivalence studies. Figure 1 depicts the solubility and dissolution assays 
in the drug discovery and development processes. 
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Figure 1 Solubility and dissolution determinations in the drug discovery and development 
stages. 
2.1.1 Kinetic solubility 
The measurement of the kinetic (non-equilibrium) solubility usually starts from the 
dissolved compound and represents the maximum solubility of the fastest precipitating 
material, which is typically not determined. The precipitating material can be any of the 
existing different solid forms of the compound, for example, polymorphic changes can 
happen even within minutes (Aaltonen et al., 2006). Also the formation of different salts 
may be possible depending on the presence of ionic species in the medium. In practice, the 
small volume (μl) of the stock solution (most often DMSO), in which the compound is 
dissolved, is added to the aqueous solution until the solubility limit is reached. 
Experiments can be performed by adding equal volumes of DMSO stock solution to the 
aqueous medium spaced a minute apart (Lipinski et al., 1997). In an alternative 
experiment, a dilution series of DMSO stock solution is prepared into separate vials 
(Kibbey et al., 2001). The kinetic solubility is defined to be the concentration at which the 
precipitation starts. 
2.1.1.1 Dimethyl sulfoxide (DMSO) as a co-solvent 
The amount of DMSO in the aqueous solution is increased in the kinetic solubility 
experiments by every addition of the DMSO stock solution. The final DMSO 
concentration varies and concentrations 0.5% (Bard et al., 2008), 1% (Chen et al., 2002b; 
Taub et al., 2002; Bard et al., 2008), 2% (Kibbey et al., 2001; Dehring et al., 2004), 5% 
(Pan et al., 2001; Bard et al., 2008) and even up to 20% (Kramer et al., 2009) have been 
reported. DMSO might induce a higher water-solubility than the compound would have 
without the DMSO due to the supersaturation or co-solvent effects (Chen et al., 2002b; 
Loftsson and Hreinsdottir, 2006; Bard et al., 2008). The co-solvents increase the solubility 
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by being miscible with water and acting as better solvents for the solute in question. 
DMSO is an efficient solvent for poorly water-soluble compounds because of its 
amphipathic structure with highly polar domain and two apolar groups enabling it to mix 
both hydrophilic (with water) and hydrophobic (organic compounds) environments 
(Santos et al., 2003). Supersaturated solutions are solutions, which have higher solute 
concentration than in the equilibrium state. The equilibrium is established between the 
solute in the solution and the excess of (undissolved) compound. DMSO enhances the 
solubility in a compound specific way (Chen et al., 2002b; Taub et al., 2002). Taub et al. 
(2002) investigated the possibilities of replacing DMSO by another co-solvent, for 
example ethanol or HPCD (hydroxypropyl-β-cyclodextrin), but the effect of enhanced 
solubility remained. According to Alsenz and Kansy (2007), the DMSO concentration 
should be kept as low as possible (1%) to reduce the potential co-solvent effect and to 
achieve better correlation with the equilibrium solubility methods. The final co-solvent 
and the amount of it should always be reported, although the solubility results obtained 
from different kinetic methods are typically not comparable to each other and the kinetic 
solubility values are not even expected to be reproducible between different kinetic 
methods (Stuart and Box, 2005). Comparison of the results is complicated because of the 
different DMSO concentrations at the end-point (Chen et al., 2002b). Di and Kerns (2006) 
have reviewed the strategies for optimizing bioassays with DMSO, including 
improvements in storage and handling. Serial dilutions in DMSO are recommended, and 
these dilutions should be added directly to the assay media. Assays should also run at the 
lowest useful concentrations.   
DMSO, the current industry standard solvent for screening purposes, has some very 
problematic features, like it suffers from the rapid uptake of water; if the water content 
gets too high in the DMSO solutions, some compounds may fall out of solution and give a 
false negative result (Homon and Nelson, 2006). DMSO is hygroscopic and can absorb 
water up to 10% of its original volume (Di and Kerns, 2006), which also causes reduced 
solubility with the crystallization in the freeze-thaw cycles. DMSO has also several 
systemic adverse effects, e.g. nausea, vomiting, diarrhea, anaphylactic reactions, 
bradycardia and heart block are reported (O’Donnell et al., 1981; Davis et al., 1990; 
Rapoport et al., 1991; Stroncek et al., 1991; Styler et al., 1992). Besides, even 20% of the 
compounds in the commercial libraries are poorly soluble in DMSO according to Balakin 
et al., 2004.  
2.1.1.2 Kinetic solubility assays  
In general, kinetic solubility values are measured in the drug discovery process to screen 
the lead compounds. A high-throughput turbidimetric method for kinetic solubility assay, 
in which the detection was based on nephelometry (Davis and Parke, 1942), was 
introduced by Lipinski et al. (1997). Detection is based on the intensity of the scattered 
light as a function of concentration. In general, kinetic solubility measurements are fast 
and suitable for the HTS processes handling more than 100.000 samples per day and cover 
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the required concentration range in assays used in early discovery (Homon and Nelson, 
2006). More details about the methods are presented in the Table 2.  
 
Table 2. Kinetic solubility in the drug discovery stage. Precipitation quantified by 
nephelometry or UV-absorbance. 
 
Nephelometrya-d Diode array UVa UV plate readerd-g 
Sensitiveness 
 
Sample volume   
 
DMSO conc. 
 
Advantages 
 
 
 
 
 
Disadvantages 
 
 
20-54 μM 
 
200-300 μl 
 
0.67-5%  
 
Colored compounds do 
not interfere, 
Shaking or 
ultrasonication is not 
required. 
 
Small undissolved 
particles cause 
misinterpretations;  
High/low  
concentrations   
can be problematic. 
5-65 μg/ml 
 
2.5 ml 
 
0.67%  
 
Accurate determination based 
on a calibration curve. 
 
 
 
 
Colored compounds miscalled 
as insoluble. 
0.5-1 μM 
 
200 μl 
 
0.5–5% 
 
Able to detect impurities 
or low UV absorption. 
 
 
 
 
Compounds should 
have sufficient 
absorbance in the 
region > 230 nm, 
Absorption of residues 
or other materials at the 
same wavelength as 
drug compounds. 
aLipinski et al., 1997; bBevan and Lloyd, 2000; cDehring et al., 2004; dHoelke et al., 2009; 
ePan et al., 2001; fChen et al., 2002b; gBard et al., 2008 
2.1.2 Equilibrium solubility 
The equilibrium (thermodynamic) solubility test is performed by dispensing a surplus of 
solid compound into a liquid medium. After reaching the equilibrium state between the 
excess of undissolved compound and saturated solution, the saturation solubility can be 
defined. To confirm that equilibrium state has been reached, the solubility has to be 
constant for several consecutive time-points, which takes several hours or days, even 
months to reach. Usually equilibrium solubility is studied in the later stages of drug 
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discovery process and it is regarded as the golden standard for development needs (Alsenz 
and Kansy, 2007). 
A classical equilibrium solubility assay is the shake-flask method. In this method an 
excess of solid drug is dispensed into aqueous solution, after which the container is shaken 
at certain speed and temperature. Samples are collected regularly, usually during 24-48 
hours, to make certain that the equilibrium plateau has been reached. The shake-flask 
method has not been officially defined in pharmacopoeias, so several protocols exist 
(Avdeef et al., 2000; Blasko et al., 2001; Kerns, 2001; Bergström et al., 2002; Lipinski et 
al., 2003; Chen and Venkatesh, 2004; Glomme et al., 2005; Avdeef, 2007; Zhou et al., 
2007) (Table 3).  
 
Table 3. Different protocols to perform shake-flask solubility measurements (N.A. not 
available in the article). 
 Medium  
volume (ml) 
Shaking 
(rpm) 
Residue removal Quantification 
Blasko et al., 2001 
Kerns, 2001 
Bergström et al., 2002 
 
Chen and Venkatesh, 2004 
Glomme et al., 2005 
Avdeef, 2007 
 
Zhou et al., 2007 
 
5.0 
0.45 
0.05-1.0 
 
1.0 
2.0 
2.0-20.0 
 
1.0-5.0 
 
N.A. 
N.A. 
300 
 
N.A. 
450 
N.A. 
 
600 
filtration 
filtration 
centrifugation 
 
filtration 
filtration 
filtration or 
centrifugation 
filtration or 
centrifugation 
HPLC 
HPLC 
HPLC-UV/-
fluorescence 
HPLC-UV 
HPLC-UV 
HPLC-UV 
 
HPLC-UV 
(LC-MS) 
2.2 In vitro dissolution methods for solid dosage forms 
Dissolution (dissolution rate) can be expressed by the Noyes-Whitney equation: 
 
dt
dm  = 
h
DA (Cs – Cb).     (2) 
 
The rate of mass transfer of solute molecules or ions through a static diffusion layer, 
dm/dt, is directly proportional to the area available for molecular or ionic migration, A, the 
concentration difference, Cs-Cb, and D, the diffusion coefficient of the solute (usually 
m2/s) and is inversely proportional to the thickness of the boundary layer, h. Cs is the 
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saturation solubility and Cb is the concentration of drug at a particular time in the bulk 
dissolution medium (Noyes and Whitney, 1897). If the Cb does not exceed 10% of the Cs, 
the dissolution is said to occur under sink conditions. In the table 4 are the factors 
affecting the dissolution rate.   
 
Table 4. Factors affecting the dissolution rate. 
Term Factor Examples 
A 
 
 
 
 
Cs 
 
 
 
 
 
 
 
 
 
Cb 
 
 
 
h 
 
 
D 
Particle size and shape 
- Aggregation 
 
- Crystal shape affected by crystallization process  
 
Solid-state form  
- Change in the solid form properties 
Complex formation  
Salts 
- common ion-effect 
Solubilizing agents 
Temperature 
Dissolution medium 
- e.g. pH (ionizable compounds), co-solvents 
 
Volume of medium 
Processes that remove dissolved solute from the medium  
- e.g. adsorption 
 
Thickness of boundary layer 
- affected by agitation 
 
Diffusion coefficient of solute in the dissolution medium   
- affected by the viscosity of medium 
 
Dokoumetzidis and Macheras, 
2006 
Fini et al., 1995 
 
Pudipeddi and Serajuddin, 2005 
 
Brewster and Loftsson, 2007 
Serajuddin, 2007 
 
Bakatselou et al., 1991 
Hill and Petrucci, 1999 
 
Taub et al., 2002 
 
Dressman et al., 1998 
 
Lindenberg et al., 2005 
 
 
Alsenz et al., 2007 
 
 
Dressman et al., 1998 
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The importance of dissolution to the drug absorption and bioavailability is emphasized in 
the Biopharmaceutics Classification System (see also later chapters) by Dn, dissolution 
number (Amidon et al., 1995): 
 
Dn = 
Diss
res
t
t
           (3) 
 
where tres is the mean intestinal residence time (ca. 180 min, which differs from MAD 
model time) and tDiss is the time required for a drug particle to dissolve. From the above 
equation it is obvious that the higher the Dn, the better the drug absorption, and the 
maximal drug absorption is expected when Dn>1. In the case of Dn<1, the dissolution 
process is too slow to have been finished before the drug has passed by its intestinal 
absorption site. The nature of limitation can be equilibrium or kinetic solubility. In the 
equilibrium situation not enough fluid is available in the GI tract and in the kinetic 
situation the entire dose of the drug dissolves too slowly. To ensure the bioavailability of 
poorly water-soluble drugs the full drug dose should dissolve during the GI residence 
time. To ascertain fast enough dissolution at the absorption window of the GI tract, 
various formulation strategies are needed. 
2.2.1 Regulatory dissolution methods 
The official in vitro dissolution methods for oral immediate release (IR) solid dosage 
forms are described in the pharmacopoeias (e.g. The European Pharmacopoeia, Ph. Eur., 
2009; United States Pharmacopoeia, USP, 2009; The International Pharmacopoeia, 
Int.Ph., 2009; Japanese Pharmacopoeia, JP, 2009). The in vitro dissolution test can be 
performed by the stirring or flow modes. The stirring mode includes simple, robust and 
well standardized basket (Apparatus I) and paddle (Apparatus II) methods, which are 
represented in all the leading pharmacopoeias. The flow mode includes the reciprocating 
cylinder or flow-through cells, which are described e.g. in Ph. Eur. and USP. A 
comparison of dissolution testing conditions by the stirring methods are presented in Table 
5. Despite of the harmonization of dissolution tests between the USP, Ph. Eur. and JP, 
some differences still do exist (EMEA, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
19
Table 5. The official dissolution testing conditions.     
 Ph. Eur. USPa JP 
Medium 
Volume (ml) 
pH of buffers 
Temperature (oC) 
Enzymes 
 
Agitation (rpm) 
Basket method 
Paddle method 
 
900 
1.0-7.5 
37±0.5 
case-by-case 
 
 
100 
50 
 
500, 900, 1000  
1.2-6.8  
37±0.5 
case-by-case 
 
 
50-100   
50-75  
 
900 
1.2-6.8 
37±0.5 
case-by-case 
 
 
100 
50 
aFDA, 1997a 
2.2.2 Initial steps of the dissolution process      
The main difference between the stirring methods described above and intrinsic 
dissolution method (IDR) (Ph. Eur., 2009; USP, 2009) or channel flow cell technique 
(Compton et al., 1988; Brown et al., 1993; Compton et al., 1993) is that in the latter 
methods only one tablet side is exposed to the dissolution medium (Figure 2). 
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Figure 2 Schematic illustrations and liquid flows of a) Intrinsic dissolution apparatus and b) 
Channel flow cell method. 
Intrinsic dissolution rate (IDR) 
 
The IDR method is based on the idea that the dissolution environment (surface area, 
temperature, pH, stirring speed and ionic strength) of pure drug substances is kept constant 
during the whole measurement (Nicklasson et al., 1981; Nicklasson et al., 1985). The fluid 
flow has been studied (Mauger, 1996; Mauger et al., 2003) and the IDR method has also 
been successfully miniaturized requiring only 5 mg of pure drug (Berger et al., 2007; 
Persson et al., 2008). As an advantage the compression pressure, dissolution medium 
volume or die position have no significant effect on IDR (Yu et al., 2004). The IDR of the 
pure drug is an important physicochemical property, which is useful, e.g., when predicting 
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problems related to the absorption of the drugs. The evaluation of the IDR of pure drug 
substances demonstrates chemical purity and equivalence.   
The intrinsic rate (j) is expressed in terms of dissolved mass of compound per time per 
exposed area (mg min-1 cm-2): 
 
j = 
A
V  
dt
dc ,     (4) 
 
where V is volume, A is area of the drug disk, c is concentration and t is time. IDR can 
also be calculated by Levich equation (Yu et al., 2004): 
 
j = 0.62 ( 6/1
2/13/2
v 
D ) Cs,    (5) 
 
where Cs is saturated solubility or concentration, D is the diffusion coefficient, ω is the 
angular velocity of the rotating disk and v is the kinematic viscosity of the dissolution 
medium. It is assumed in this model that equilibrium is predominant at the interface of 
solid and liquid, and the liquid at the interface is the same as the liquid in bulk dissolution. 
Since the intrinsic dissolution is primarily a rate phenomenon, it is expected to correlate 
more closely with in vivo drug dissolution dynamics than solubility. Still, the correlation 
between the solubility and intrinsic dissolution rate of a drug compound has been found 
both in water or aqueous buffer solutions (Nicklasson et al., 1981; Gu et al., 1987; 
Nicklasson et al., 1988) and water-ethanol binary solvent systems (Nicklasson and Brodin, 
1984). Also the correlation between the IDR and BCS solubility classification has been 
found by Yu et al. (2002).   
 
Channel flow cell (CFC) method  
 
The hydrodynamics (laminar flow) in the channel flow cell (CFC) is well defined 
(Compton et al., 1988; Brown et al., 1993; Compton et al., 1993), which enables 
acquisition of quantitative information of the dissolution kinetics and mechanism, even at 
early stages of the process, and modelling. This information is often lost in the traditional 
dissolution methods. In addition, accurate modelling of the mass transfer in the CFC 
enables comparisons of different dissolution mechanisms and experimental results. The 
flow rate in the channel presents an additional experimental parameter that can be used to 
tune the rate of mass transfer in the flowing aqueous phase. 
When the dissolution experiments involve pure compounds, the model consists of a 
convective mass transfer in the medium coupled to a dissolution reaction at the tablet 
surface with an equilibrium constant, K (Singh and Dutt, 1985). Theoretical expression to 
the concentration, cb, as a function of time: 
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cb (t) = K (1 – exp (- V
mA t))     (6)  
 
where m is the mass transfer coefficient, A is the exposed area of the tablet and V is the 
volume of the dissolution medium and t is time. 
In the CFC the tablet is located in the cavity so that the disintegration of the tablet is 
hindered when, e.g., the properties of disintegration excipients do not affect the 
dissolution as in the traditional methods. In the case of tablet formulations, it is not 
expected that the mass transfer coefficient would be equal for all tablets and only a 
function of the flow rate. With tablet formulations including excipients, diffusion and 
dissolution inside the tablet and the sink conditions were included in the model (Higuchi, 
1961): 
 
t +  o
T
b
cAD
tcV
2
2 )(  + (
mA
V + o
T cAD
KV
2
2 ) ln (
K
tcK b )(− ) = 0  (7) 
 
where DT is the diffusion coefficient of the drug inside the tablet and c0 the concentration 
of the drug in the dry tablet.    
The combination of dissolution testing and solid-state analysis has been proposed to be 
called physico-relevant dissolution testing (Aaltonen and Rades, 2009). Recently, the 
channel flow method has been utilized, e.g., to study the solvent-mediated solid-state 
transformation during dissolution (Aaltonen et al., 2006; Lehto et al., 2008), the solid-state 
behavior during dissolution of amorphous drugs (Savolainen et al., 2009) and the effect of 
texture on the intrinsic dissolution behavior (Tenho et al., 2007). 
2.2.3 In vivo mimicking of dissolution methods  
Alternative methods have been developed to complete the lacks of the regulatory methods. 
In general, the official basket and paddle dissolution techniques suffer from high 
variability in results (Achanta et al., 1995; Qureshi and McGilvery, 1999). Further, the 
basket method suffers, e.g., from the hydrodynamic ‘dead zone’ under the basket, 
blockings in the mesh by drug or excipient and hindered visual examination of the 
disintegration process (Banaker, 1992). The paddle method, for its part, suffers above all 
from the coning effect (Beckett et al., 1996).   
Several unofficial in vitro dissolution methods exist (Pernarowski et al., 1968; 
Shepherd et al., 1972; Shah et al., 1973; Cakiryildis et al., 1975), some of them modified 
from the regulatory methods (Qureshi and Shabnam, 2003; Röst and Quist, 2003). The 
new methods, e.g. the dissolution stress-test device, are more complicated (Garbacz et al., 
2008; Garbacz et al., 2009). This method mimics the discontinuous movements of the 
dosage form and breaks of it from the intestinal fluid in the GI tract. Even more 
complicated release and solubility testing methods are the physiologically based TIM-1 
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(stomach and small intestine) and TIM-2 systems (large-intestine) (Havenaar and 
Menikus, 1994). For example the TIM-1 has four compartments simulating stomach, 
duodenum, jejunum and ileum. The TIM devices mimic, e.g., the peristaltic movements, 
GI transition times, pH of GI tract and secretion of bile, gastric acids and enzymes. Results 
with the TIM-1 system compared to the in vivo data have been similar (Blanquet et al., 
2004; Souliman et al., 2006). Still, the new dissolution devices need a large volume of 
medium, which enables their use only in the later stages of drug development process.      
2.3 In vivo dissolution  
The most common and patient convenient way to deliver drugs is the oral route. After oral 
administration, the physiology of the GI tract affects the dissolution and absorption of the 
drug. The GI tract is divided into three major anatomical regions (the stomach, the small 
intestine and the colon), from which the small intestine is the most important site for drug 
absorption. The length of the small intestine is about 3.3 meters (Ho et al., 1983) and the 
area available for absorption is about 200 m2 (Ashford, 2007). The large area of small 
intestine is possible because of the folds of Keckring, the villi and the microvilli. The 
absorption sites of drugs in the small intestine differ from each other. Highly permeable 
drugs absorb mainly at the tips of the villi and the low permeability drugs may diffuse 
down the length of the villi to be absorbed over a larger surface area (Artursson et al., 
2001). The main anatomical barrier for the drug absorption is the enterocytes, which 
apical side constitutes of densely packed microvilli and the lateral membranes connected 
through tight junctions. The absorption routes from the intestinal epithelium are based on 
paracellular passive diffusion, transcellular pathway (passive diffusion, carrier-mediated, 
receptor-mediated) or carrier-mediated efflux pathways (Back and Rogers, 1987; Tsuji 
and Tamai, 1996; Stenberg et al., 2000; Artursson et al., 2001; Martinez and Amidon, 
2002).  
Before possible absorption the drug needs to be released and dissolved from the solid 
dosage form to the GI fluids. The pH, composition, volume and hydrodynamics of the 
contents in the lumen are the main factors in the dissolution of drugs in the GI tract 
(Dressman et al., 1998).  
2.3.1 Effect of pH  
The pH in the GI tract varies depending on the anatomical region and the nutrition state. 
Stomach has an acidic pH in the fasted state, median values are found between 1.7 and 2.4 
with high interindividual variations. After meal the gastric median pH increases up to 6.4-
6.7 depending on the type and volume of the meal. The pH of stomach is returned acidic 
2-4 hours after the meal (Dressman et al., 1990; Kalantzi et al., 2006a). Intestinal pH is 
higher than the gastric pH. In the fasting state the median pH is about 6.1-7.2 (Lindahl et 
al., 1997; Kalantzi et al., 2006a; Moreno et al., 2006; Brouwers et al., 2006; Clarysse et 
al., 2009b) and in the fed state 6.1-6.6 (Dressman et al., 1990; Kalantzi et al., 2006a; 
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Clarysse et al., 2009b), with less interindividual variation compared to the gastric pH 
(Table 6). The pH has been reported to be similar in the jejunum (median 7.0) and 
duodenum (median 6.5) in the fasted state (Moreno et al., 2006). The pH in the colon 
depends on the region. In the caecum the pH is around 5.6-6.6, increasing up to 7-7.5 in 
the distal parts of the colon (Fallingborg et al., 1989). Especially, for ionizable compounds 
the pH of the GI tract is important; Ratio of unionized and ionized forms depends on pH. 
Usually the ionized form has higher solubility than unionized form. For example weak 
acids has slow solubility and dissolution in stomach, whereas they can achieve high 
solubility and dissolution in intestine. On the contrary, for poorly soluble compounds the 
pH of GI is not the rate-limiting step for dissolution, but in the GI tract is not enough fluid 
available or the entire dose of the drug dissolves too slowly (Dressman et al., 1998). 
2.3.2 Role of bile acids and phospholipids  
Bile is secreted to the small intestine. The secretion of bile is at maximum about 30 
minutes after ingestion of a meal and the gallbladder is emptied up to 73% (Mathus-
Vliegen et al., 2004). The major components of bile are the bile acids, phospholipids, 
cholesterol and free fatty acids. The bile salt concentration compared to the phospholipid 
concentration has been reported to be 2-3:1 in the fed state and 9:1 in the fasted state 
(Persson et al., 2005; Kalantzi et al., 2006b). Bile has an important role in improving 
solubility and dissolution of poorly water-soluble drugs. Especially, bioavailability of 
poorly soluble drugs increases manifold when administered in fed state or with lipid-based 
formulations (Persson et al., 2005; Sunesen et al., 2005; Kalantzi et al., 2006b). The effect 
could result from decreased first pass metabolism, lymphatic uptake (Porter et al., 1996), 
inhibition of efflux transporters (Wu et al., 2005) or increased solubility (Persson et al., 
2005; Kalantzi et al., 2006b) and dissolution. Bile acids enhance solubility due to the 
wetting (Bakatselou et al., 1991) and/or solubilization effect (Bakatselou et al., 1991; 
Charman et al., 1993) which has been demonstrated e.g. with steroidal compounds 
(Mithani et al., 1995).  
For the prediction of in vivo dissolution and solubility, simulated intestinal fluids, like 
FaSSIF and FeSSIF, have been developed (Galia et al., 1998). Jantratid et al. (2008) 
proposed further a set of media to represent various regions of the gastrointestinal tract: 
fasted state simulated gastric fluid (FaSSGF) (Vertzoni et al., 2005), fed state simulated 
gastric fluid (FeSSGF), fasted and fed state simulated upper small intestine fluids 
(FeSSIF-V2, FaSSIF-V2) and various media for conditions that represent digestion. 
Simulated media contain e.g. lecithin and sodium taurocholate to represent the 
phospholipids and the bile salts. 
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Table 6. The compositions of fasted and fed state HIF. 
 Fasted HIF Fed HIF 
Bile Acids/salts (mM) 
 Taurocholic acid (%) 
 Glycocholate (%) 
 Glycochenodeoxycholate (%) 
 Glycodeoxycholate (%)  
 Taurochenodeoxycholate (%) 
 Taurodeoxycholate (%) 
2.0-3.5a-e 
22.0a, 44.95±18.17d 
25.0a, 17.21±6.37d 
18.0a, 13.77±9.59d 
1.0a, 10.40±7.32d 
20.0a, 7.89±2.16d 
1.0a, 4.71±2.47d 
8.0-15.0a,g,i
18.0a 
25.0a 
20.0a 
13.0a 
15.0a 
9.0a 
Phospholipids (mM) 
Lyso-phosphatidylcholine (%) 
Phosphatidylcholine (%) 
0.2–0.6a,i
99.0a 
1.0a 
0.07-4.8a,g,i
87.0a 
13.0a 
Parameters 
Osmolality (mOsm/kg) 
pH 
Buffer capacity (mmol/l pH-1) 
 
200–271b-d 
6.6-7.5a-f 
2.4-2.8a-e 
 
287k 
5.1-6.1f,j,k 
13.2-14.6a 
 
aPersson et al., 2005; bClarysse et al., 2009b; cLindahl et al., 1997; dMoreno et al., 2006; 
eBrouwers et al., 2006; fKalantzi et al., 2009a; gMansbach et al., 1975; hSheng et al., 2009; 
iArmand et al., 1996; jClarysse et al., 2009a; kDressman et al., 1998  
2.3.3 Hydrodynamics in gastrointestinal (GI) tract  
In the fasted state GI tract has only little or no motoric activity. Still, the ‘’house-keeping’’ 
waves empty the stomach regularly about every two hours from the stomach to the small 
intestine. In the fed state mixing is more active and dissolution is expected to be more 
efficient. The gastric emptying time is higher after meal ingestion or after large liquid 
volume compared to the fasted state and the lipid contents of the meal increases the transit 
time further (Sunesen et al., 2005). For small intestine the transit time varies from three to 
four hours and stays the same whether the drug is taken with meal or not (Sunesen et al., 
2005). Instead, the flow velocity varies in different parts of the small intestine e.g. being 
higher in the ileum as in the jejunum (Ho et al., 1983). The volume of stomach and 
intestine in fasted state is 20-30 ml and 120-350 ml (Dressman et al., 1998). Under fed 
conditions the volume might be as high as 1500 ml in the upper intestine. 
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2.4 In vitro in vivo (IVIV) correlation  
IVIV correlation has been defined as ‘a predictive mathematical model describing the 
relationship between in vitro property of a dosage form and relevant in vivo response, for 
example plasma drug concentration or amount of drug absorbed’ (FDA, 1997b). IVIV 
correlation serves as a surrogate for in vivo data and is also used to validate the dissolution 
methods and in quality control. Three main levels of the IVIV correlation have been 
determined: level A, level B and level C (FDA, 1997b). The level A correlation represents 
the linear relationship between in vitro dissolution rate and in vivo input curves of the drug 
from the dosage form. Level A correlation is the most informative and recommended, if 
possible. Table 7 compares the release testing in vitro and in vivo. Medium, volume, 
hydrodynamics, temperature, location of the formulation and amount of the drug are 
considered.  
 
Table 7. Differences between the in vitro and in vivo release testing of immediate release 
drug products. 
Parameter IN VIVO IN VITRO 
Medium GI fluids  
 
Water, 
Buffer solutions, 
Simulated media 
Volume 250 ml (fasted state) 
(interindividual variation) 
Depending on the device 
(from μl:s to1000 ml) 
Hydrodynamics GI motility  Mechanical agitation, 
Depending on the device 
Temperature Body temperature Depending on the test 
circumstances 
Location of the formulation Variation with time Depending on the device 
Amount of the drug Decreases as it is absorbed 
(e.g. open system) 
Constant in closed systems, 
Decreases in open systems 
2.4.1 Biopharmaceutics Classification System (BCS) 
The meaning of BCS is to correlate in vitro drug product dissolution and in vivo 
bioavailability (Amidon et al., 1995). In practice, BCS divides drugs into four classes 
according to their solubility and permeability properties. The drugs are classified as highly 
soluble if the highest orally administered single dose can be completely dissolved in 250 
ml of water, independently of the pH value at the range of 1.0–7.5 at 37 oC. Further, the 
drug is considered to be highly permeable when 90% or more of the orally administered 
dose is absorbed in the small intestine. The ideal drug would be class I drug having high 
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solubility and permeability. The dissolution test for these drugs is only to verify that the 
drug is rapidly released from the dosage form. For the BCS class I drugs the IVIV 
correlation exist if dissolution rate is slower than gastric emptying rate. For BCS class II 
drugs the drug absorption is expected to be dissolution limited and IVIV correlation 
should exist if the dose is not very high. For BCS class III drugs limited or no IVIV 
correlation is expected because permeability is the rate limiting step. These drugs dissolve 
rapidly, while the slow absorption restricts bioavailability during the passage in the 
absorption site in the GI tract. The BCS class IV drugs are often not very suitable for oral 
administration at all, so limited or no IVIV correlation is expected.     
Fleischer et al. (1999) noticed that food (high-fat meals) effects to the extent of 
bioavailability could generally be predicted based on the BCS. For example, high-fat 
meals have no significant effect on the extent of availability for class I drugs, although 
food may delay the stomach emptying time. Class II drugs would benefit from high-fat 
meals, e.g., because of additional solubilization and inhibition of efflux transporters in the 
lumen. High-fat meal effects would be decreased if the class II drugs were formulated 
towards having better solubility. 
2.4.2 Biopharmaceutics Drug Disposition Classification System (BDDCS) 
In 2005 Wu and Benet represented a modified version of BCS called Biopharmaceutics 
Drug Disposition Classification System (BDDCS) (Table 8), which is used in the 
prediction of overall drug disposition, including the rates of elimination routes and the 
effects of efflux and absorptive transporters on oral drug absorption. Accordingly, the 
extent of drug metabolism would be a better predictor than the 90% absorption 
characteristic. It was noticed that BCS class I and II compounds are eliminated primarily 
via metabolism, while class III and IV compounds end up unchanged into the urine and 
bile; if the major route of elimination for a drug is metabolism, then the drug exhibits the 
properties of high permeability compounds, and if the major route of elimination is renal 
and biliary excretion of unchanged drug, the drug is classified as low permeability 
compound. Using the extent of metabolism instead of permeability (BCS) changed the 
classification of 10 drugs, changed 11 multiple classified drugs to one class, and added 38 
drugs to the totally 168 drugs’ BDDCS list. The BDDCS predicted 93% of the drugs’ 
permeabilities correctly related to major route of elimination (Benet et al., 2008).   
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Table 8. The Biopharmaceutics Drug Disposition Classification System by Wu and Benet 
(2005). The major route of elimination (metabolized vs. unchanged) serves as the 
permeability criteria.  
Class I 
High Solubility 
Extensive Metabolism 
Class II 
Poor Solubility 
Extensive Metabolism 
Class III 
High Solubility 
Poor Metabolism 
Class IV 
Poor Solubility 
Poor Metabolism 
 
The BDDCS can also predict the effects of transporters. According to the Wu and Benet 
(2005), the transporter effects are minimal for class I drugs; efflux transporter effects 
predominate for the class II drugs and transporter-enzyme interplay in the intestines is 
important for the CYP3A substrates and phase 2 conjugation enzymes; absorptive 
transporter effects predominate for the class III drugs and; absorptive or efflux transporter 
effects could be important for the class IV drugs.  
2.4.3 BCS Biowaivers   
BCS is utilized for the so-called biowaivers, which means that in vivo bioavailability 
and/or bioequivalence studies may be waived. In that case a dissolution test could be 
adopted as the surrogate basis for the decision as to whether two pharmaceutical products 
are equivalent. According to the regulatory authorities (e.g. FDA, 2000; EMEA, 2002), 
only highly soluble and highly permeable BCS class I drugs can have a biowaiver status in 
IR solid oral-dosage forms. Furthermore, biowaiver products may not contain excipients 
that could influence the absorption of a drug compound, drug compound can not have a 
narrow therapeutic index, and the product can not be designed to be absorbed from the 
oral cavity. 
Yu et al. (2002) have proposed to extend the biowaiver status to BCS class II and III 
drugs. They criticized the regulatory limits of solubility and permeability being too strict. 
The changes they proposed were to narrow the required solubility pH range to the 1.0-6.8 
and to reduce the high permeability requirement from 90% to 85%. Also the boundaries 
for solubility of acidic BCS class II drugs have been shown to be too restrictive by 
Yazdanian et al. (2004). Other studies (Cheng et al., 2004; Kortejärvi et al., 2005; 
Kortejärvi et al., 2007; Kortejärvi et al., 2010) and reports (WHO, 2006) have been 
published recommending a biowaiver status for BCS class III drugs. Benet et al. (2008) 
recommended the regulatory authorities to add the extent of drug metabolism (i.e. 90% 
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metabolized) as an alternative method for the extent of drug absorption (i.e. 90% 
absorbed) in defining class I drugs suitable for biowaivers. This would increase the 
number of class I drugs eligible for biowaivers.    
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3 Aims of the study  
The overall aim of the study was to develop predictive, reliable and rapid kinetic and 
equilibrium solubility and dissolution screening methods, which do not require large 
amounts of compounds and would (ultimately) correlate well with in vivo results. Several 
solubility and dissolution testing methods were developed and characterized by using 
different volumes of aqueous buffer solutions and fasted state HIF as media. The specific 
aims of the study were:    
 
1.  To construct and characterize the channel flow method and to compare it with 
the regulatory USP basket and intrinsic dissolution methods (I, II).  
 
2.  To miniaturize dissolution testing stepwise from the regulatory dissolution 
methods and shake-flask solubility measurements via micro dissolution method 
to the 96-well plates (micro dissolution testing is previously unpublished data).  
 
3.  To develop 96-well plate HTS methodology to determine both the equilibrium 
solubility and dissolution rate while avoiding the co-solvent(s) related 
problems. The model compounds were initially in solid form as in the 
traditional equilibrium solubility method in shake-flasks (IV).   
 
4.  To develop kinetic HTS drug solubility testing method suitable for compounds 
having problems with UV absorption. The method is based on compounds’ 
surface tension measurements by a novel microtensiometer (III).    
 
5. To compare the aqueous equilibrium solubility/dissolution results in the 96-
well plate method with corresponding testings in fasted state HIF medium (IV). 
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4 Experimental 
4.1 Materials 
4.1.1 Chemicals (I-IV) 
The model compounds and references to the corresponding publications are summarized 
in Table 9. The model compounds were from Orion Pharma (Finland) except for 
antipyrine (Aldrich Chemical Company Inc., USA), diclofenac sodium (Sigma-Aldrich 
Chemie GmbH, Germany), indomethacin (Fluka Biochemika, Italy), piroxicam (Hawkins 
Inc., USA) and theophylline anhydrous (Helm AG, Germany). As tablet excipients were 
used microcrystalline cellulose (MCC) (Avicel PH 102, FMC, Ireland) (I, II), lactose 
(monohydr., 80 M, DMV International, The Netherlands) (I, II), magnesium stearate 
(University Pharmacy, Finland) (II) and talc (Pharmia Oy, Finland) (II). All the other 
laboratory chemicals were of analytical grade. 
4.1.2 Human intestinal fluid (HIF) (IV) 
The HIF was collected from five volunteers after an overnight fast by introducing one 
double-lumen catheter (Salem Sump Tube 14 Ch, external diameter 4.7 mm, Sherwood 
Medical, Petit Rechain, Belgium) in the duodenum (D2/D3) via the mouth. Sampling of 
HIF was continued for 3 hours every 15 minutes. HIF was stored at -30oC or colder and 
before solubility studies the individual HIF samples were pooled together. 
4.2 Methods 
4.2.1 Preparation of tablets (I, II) 
Tabletting masses of 200 g (I) and 150 g (II) were prepared. The powders were mixed for 
15 min in turbula mixer (Turbula T2C, Willy A. Bachofen AG Machinenfabrik, 
Switzerland). Tablets were directly compressed with a single punch tabletting machine 
(Korsch EK-0, Erweka Apparatebau, Germany) using a flat punch with a diameter of 9 
mm. The target weights of tablets were 250 mg. 
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Table 9. The model compounds.    
Model compound 
 
Molecular 
structure 
BCS 
class 
 
pKa 
 
Acidic 
/basic 
 
Paper 
Acetylsalicylic acid C16H12O6 I 3.48 A I 
Antipyrine C11H12N2O I 0.7 B IV 
Atenolol C14H22N2O3 III 9.16 B IV 
Caffeine C8H10N4O2 I 0.73 B IV 
Carbamazepine C15H12N2O II 13.94 A IV 
Diclofenac sodium C14H10Cl2NNaO2 II 4.18 A IV 
Furosemide C12H11ClN2O5S IV 3.04 A IV 
Hydrochlorothiazide C7H8ClN3O4S2 III 8.95 A IV 
Ibuprofen C13H18O2 II 4.41 A III, IV 
Indomethacin C19H16ClNO4 II 3.93 A III, IV 
Ketoprofen C16H14O3 II 4.23 A IV 
Metformin HCl C4H12ClN5 III 13.86 B IV 
Metoprolol tartrate C15H25NO3 I 9.17 B IV 
Naproxen C14H14O3 II 4.84 A IV 
Phenytoin sodium C15H11N2NaO2 II 8.33 A IV 
Piroxicam C15H13N3O4S II 3.80,4.50, 
13.33 
A/B IV 
Propranolol HCl C16H22ClNO2 I 9.14 B IV 
Ranitidine HCl C13H23ClN4O3S III 8.40 B IV 
Rifampicin C43H58N4O12 II 9.92 A IV 
Spironolactone C24H32O4S IV N.A. N.A. IV 
Theophylline 
anhydrous 
C7H8N4O2 II 8.60,1.70 A/B II 
Trimethoprim C14H18N4O3 II 7.2 B IV 
4.2.2 Dissolution methods 
4.2.2.1 Basket method (I, II) 
USP basket method (Sotax AT 7, Sotax, Switzerland) was used as a reference dissolution 
method (USP XXVI, 2003). The rotational speed was 50 rpm, the volume of medium was  
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900 ml and the temperature was 23oC. The samples were analyzed by a spectrophotometer 
(Perkin-Elmer Lambda 2, Germany).  
4.2.2.2 Intrinsic dissolution rate method (I, II) 
The intrinsic dissolution test was done according to the USP XXVI (2003), which is based 
on Wood’s rotating disk method (Wood, 1965). The model compounds (100 mg) were 
pressed with a hydraulic pressure of 1500 kg (Pye Unicam, UK) and rotated at 50 rpm in 
900 ml of the medium at the temperature of 23oC. (Sotax AT 7, Sotax, Germany). The 
samples were conducted into a spectrophotometer (Perkin-Elmer Lambda 2, Germany) for 
analyses.  
4.2.2.3 Channel flow method (I, II) 
In the channel flow system only one tablet surface was in contact with the media (Figure 
3). The tablet was located at the centre of the channel flow cell in order to avoid the edge-
effects (Compton et al., 1988). The flow rate of the aqueous phase was controlled by a 
peristaltic pump (Ismatec IPN-12, Switzerland) and temperature (23oC) by a thermostatted 
bath. The channel flow cell was coupled to a UV-VIS spectrophotometer (HP8541A, 
Hewlett-Packard, USA). 
 
 
 
Figure 3 a) The channel flow cell and b) the channel flow test apparatus. Modified from 
publications I and II 
.  
4.2.2.4 Micro dissolution method (previously unpublished data) 
By this method the solubility of selected model compounds (ibuprofen, ketoprofen, 
indomethacin and piroxicam) was determined in 0.1 M hydrochloric acid solution in pH 
1.2 and 6.8 buffer solutions and in biorelevant medium, FaSSIF. Excess of drug 
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compound was added into 2 ml flat-bottomed test tubes of the micro dissolution apparatus 
μDISS® (pION, USA). Dissolution medium was added into the test tubes and the solution 
was stirred at 180 rpm using magnet stirrers. The temperature of the test solutions was 
maintained at 37oC with the aid of a water bath surrounding the test tube block. The test 
solutions were kept under these circumstances for 3 hours after which the solutions were 
filtered using preheated Millipore PVDF 0.45 μm filters. The solutions were then left at 
37oC for 24 hours and the concentration of the solutions were measured by detecting the 
UV absorbance of the solutions in situ.     
Quantification of the sample solutions was determined against a calibration curve with 
four to five dilutions of standard stock solution. The concentrations of the solutions were 
determined at the absorption maximum wavelength. Further, to assure the buffer capacity 
of the solutions, pH of the sample solutions was measured after the solubility runs.  
4.2.2.5 96-well plate method (IV)   
Model drugs were first dissolved into a presolvent (methanol or water), and the presolvent 
solutions were then pipetted into 96-well plates (96F untreated 260895, Nunc, Denmark), 
after which the presolvent was evaporated in order to avoid co-solvent effects. After 
evaporation, 250 μl of the medium was added to the wells and the 96-well plates were 
shaken orbitally at 600 rpm (Heidolph titramax 100, Germany). Samples were withdrawn 
after 30 min, 1, 2, 5, 24 and 30 hours and pipetted into UV 96-well plates (UV FB 
microtiter plates 8404, Thermo Fisher Oy, USA) for analyses with UV plate reader 
λ=230-400 nm (Varioskan, Thermo Electron corporation, Finland). The tests were 
performed at 23oC. 
4.2.3 Solubility methods 
4.2.3.1. Shake-flask method (III, IV) 
Shake-flask method was used as a reference method in the solubility tests (Lipinski, 
2003). The model compounds were weighted into 25 ml (III) or 40 ml (IV) glass vials, 
which were mixed by magnetic stirrer at 100 rpm at 23oC during the tests. Samples were 
taken after 1, 2, 3, 4, 5 and 24, even after 30 hours for some compounds, until the 
equilibrium plateau was reached. Samples were filtered (0.45 μm, Minisart, Sartorius, 
UK) before analyses by UV-spectrophotometry (Pharmacia LKB, Ultrospec, Sweden).  
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4.2.3.2 96-well plate method (IV)   
The method was described in chapter 4.2.2.5. 
4.2.3.3 Surface tension based kinetic HTS solubility method (III) 
The model drugs were first dissolved into a presolvent (methanol, ethanol or DMSO). 12-
22 samples were prepared so that the first one had a drug concentration of ca. 100 mg/ml, 
and each subsequent sample was diluted to half the concentration of the previous one. 
Final sample was always a blank sample with no drug. Then, the presolvent solutions were 
added to the aqueous medium in the 96-well plate by a volume of 50 μl. Surface tension 
based measurements were performed with recently introduced Delta-8 multichannel 
microtensiometer (Kibron Inc., Finland).  
4.2.4 Analyses 
4.2.4.1 Analyses of human intestinal fluid (HIF) (IV)  
Bile salts were measured by GC-MS-selected ion monitoring analysis developed by 
Lütjohann et al. (2004). Free bile acids were extracted with diethylether and 
trimethylsilylated after alkaline hydrolysis and acidification. The chromatographic 
separation was performed with a DB-XLB capillary column in a constant flow mode of 
0.8 ml/min with a final temperature of 290oC having helium as a carrier gas. 
Total phospholipid levels were determinated enzymatically according to Gurantz et al. 
(1981), using phospholipase D and choline oxidase. The reagent kit was from Wako 
Chemicals (Neuss, Germany). 
4.2.4.2 Solid-state characterization (IV) 
X-ray powder diffraction (XRPD) was used to study the solid state forms of the model 
compounds and to confirm possible (pseudo)polymorphic changes. Measurements were 
done by an X-ray powder diffraction theta-theta diffractometer (Bruker AXS D8 advance, 
Bruker AXS GmbH, Germany). The XRPD experiments were performed in symmetrical 
reflection mode with CuKα radiation (1.54 Å) using Göbel Mirror bent gradient multilayer 
optics. The scattered intensities were measured with a scintillation counter. The angular 
range was from 5o to 30o with the steps of 0.1o and the measuring time was 20 s/step.  
The reference codes to identify experimental polymorphs were from CSD database 
(Cambridge Structural Database, The Cambridge Crystallographic Data Centre, UK) 
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(Allen, 2002). The reference crystal structure codes were for diclofenac form I (P21/c) 
SIKLIH02 (Castellari and Ottani, 1997), diclofenac form II (C2/c) SIKLIH05 (Muangsin 
et al., 2004), diclofenac form III (Pcan) SIKLIH04 (Jaiboon et al., 2001), indomethacin α-
form INDMET2 (Chen et al., 2002a), indomethacin γ-form INDMET (Kistenmacher and 
Marsh, 1972), piroxicam monohydrate CIDYAP0 (Bordner, 1984), piroxicam α-form 
BIYSEH06 (Vrecer et al., 2003), piroxicam β-form BIYSEH (Kojic-Prodic et al., 1982) 
and spironolactone polymorph 1 from acetone ATPRCL10 (Dideborg and Dupont, 1972). 
Differential scanning calorimetry (DSC) was used to further confirm the XRPD 
results. The thermal analyses were performed with a Mettler DSC 823e (Mettler-Toledo 
AG, Switzerland) and analyzed by STARe software (Mettler-Toledo AG, Switzerland). 
Samples were weighted (4-5 mg) to the aluminium pans and crimped by aluminium caps 
with a pinhole. The samples were heated at the rate of 10oC/min from 25oC to the 10oC 
above the melting point of each compound. The measurements were performed under N2 
atmosphere and the calibration was performed with indium. 
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5 Results and discussion 
5.1 Dissolution testing 
5.1.1 Channel flow method vs. the regulatory dissolution methods (I, II) 
Dissolution profiles of pure acetylsalicylic acid and theophylline from the channel flow 
method correlated well with the intrinsic dissolution profiles. In both methods the 
dissolution rate of acetylsalicylic acid at the time-point 25-min was around 5-10 mg/cm2 at 
pH 1.2 and around 20-25 mg/cm2 at pH 6.8 (I). The dissolution rates of theophylline at the 
time-point 10-min were around 11-12 mg/cm2 at pH 1.2 and 10 mg/cm2 at pH 6.8 by both 
the methods (II).  
The solubility of acetylsalicylic acid tablets (I) containing microcrystalline cellulose 
(MCC) (compositions A and C) was slightly increased by the lowering pH in the channel 
flow method opposite to the basket method. This could be due to the MCC swelling 
properties being in more important role in the channel flow method compared to the 
solubility of acetylsalicylic acid. Swelling of MCC affects the flow and the mass transfer 
characteristics hindering MCC’s disintegrating effect of the tablet in the CFC. The 
dissolution results with tablets containing only lactose as an excipient correlated well 
between the methods and the rank order of the dissolution profiles with all tablet batches 
(A-C) was similar by both methods (Figure 4). 
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Figure 4 Channel flow dissolution of acetylsalicylic acid tablet formulations A-C at pH 1.2 (a) 
and at pH 6.8 (c) (Flow rate was ca. 190 ml/h). Dissolution of acetylsalicylic acid 
with the USP basket method at pH 1.2 (b) and at pH 6.8 (d). Modified from paper I.      
The tablet compositions were more complicated with theophylline (II) containing four 
excipients (MCC, lactose, talc, magnesium stearate). The amounts of MCC and lactose 
varied between the tablet batches (A-D). The drug release rate measured by the channel 
flow method was decreased as the amount of MCC was increased. The USP basket 
method gave different result; the slowest drug release was from the tablets having the 
highest amount of lactose (A) or MCC (D). The difference can be explained by the 
different dissolution set-ups. In the channel flow method the position of the tablet hinders 
the disintegrating effect of MCC and even the formulation C (MCC 56%) remained as a 
coherent matrix. From the basket method the tablet formulation C disintegrated 
immediately. Also with theophylline the two methods lead to similar conclusions (Figure 
5).  
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Figure 5 Channel flow dissolution of theophylline from tablet formulations A-D at pH 1.2 (a) 
and at pH 6.8 (c) (Flow rate was ca. 190 ml/h). Dissolution of theophylline with the 
USP basket method at pH 1.2 (b) and at pH 6.8 (d) (A , B , C, D). Modified 
from paper II.        
The main difference between the channel flow and USP basket methods is that in the 
channel flow method only one tablet surface is exposed to the dissolution medium and, 
thus, the disintegration of the tablet is hindered. This enables collection of accurate 
information from the initial steps of the dissolution process. The intrinsic dissolution 
method is based on the idea of keeping the dissolution area of pure compound constant 
(Nicklasson et al., 1981; Nicklasson and Brodin, 1984) and achieving the dissolution by 
rotating or shear-like motion in the medium, which differs from the laminar flow in the 
channel flow method (Compton et al., 1988). Also the mass transfer can be followed with 
the channel flow method, which allows comparison between the different dissolution 
mechanisms and the experimental results. Channel flow cell method is also used in the 
modelling because of the well-defined laminar flow in the CFC (Aaltonen et al., 2006; 
Lehto et al., 2008). 
 
 
 
 (b)(a) 
(c) (d)
pH 1.2pH 1.2 
pH 6.8pH 6.8 
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5.1.2 Micro dissolution studies in different media (previously unpublished 
data) 
Micro dissolution studies were performed in Orion Pharma with four model drugs 
(ibuprofen, indomethacin, ketoprofen and piroxicam) in three different media (aqueous 
solution pH 1.2, buffer solution pH 6.8 and FaSSIF) at +37oC. Table 10 presents results 
comparing equilibrium solubilities with micro dissolution, shake-flask and equilibrium 96-
well plate methods. The latter were both performed at room temperature (23±1oC).  
 
Table 10. Equilibrium solubilities (mg/ml) of four model compounds in different media 
(SF=Shake-flask, MD=Micro dissolution and HTS=equilibrium 96-well plate 
method, n=2).  
 
 
Compound 
SF 
 
pH 1.2 
MD 
 
pH 1.2 
SF 
 
pH 6.8 
MD 
 
pH 6.8 
MD 
FaSSIF 
pH 6.5 
HTS 
HIF 
pH 6.2 
Ibuprofen 
Indomethacin 
Ketoprofen 
Piroxicam 
0.07 
0.004 
0.08 
0.06 
0.05 
0.001 
0.13 
0.19 
2.9 
0.4 
5.5 
0.2 
3.5 
0.6 
5.4 
0.6 
3.3 
0.6 
5.6 
0.4 
2.0 
2.4 
3.2 
0.8 
 
As expected, the equilibrium drug solubilities by the micro dissolution and shake-flask 
methods were higher at pH 6.8 than at pH 1.2 (pKa values of the model compounds are 
mostly around 4). The micro dissolution solubilities in the pH 6.8 buffer solution and 
FaSSIF (pH 6.5) correlated well suggesting that the buffer might be an adequate medium 
at this solubility scale for the model compounds, although FaSSIF contains taurocholic 
acid and lecithin. Instead, the solubility results in HIF (pH 6.2) were somewhat lower for 
ibuprofen and ketoprofen and somewhat higher for piroxicam and indomethacin compared 
to the aqueous buffer pH 6.8 or FaSSIF pH 6.5. The compositions of fasted state HIF and 
FaSSIF are more complicated than the composition of aqueous buffer at pH 6.8 containing 
e.g. bile acids, which enhance solubility due to the solubilization effect (Bakatselou et al., 
1991; Charman et al., 1993) and/or wetting (Bakatselou et al., 1991). Here, the dissolution 
method (micro dissolution vs. 96-well plate) has important role to give similar results. 
According to our study, the medium (aqueous buffer, FaSSIF, HIF) has minor role. The 
use of HIF (and FaSSIF) in the solubility studies may have more pronounced importance 
for very low solubility compounds at the discovery stage, although the more simple, fast 
and economic methods/techniques are preferred also there.  
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5.1.3 Dissolution profiles in 96-well plate (IV) 
Besides the equilibrium solubility determinations, the 96-well plate method can be used to 
study the dissolution rates of drugs as a function of time (IV). Figure 6 distinguishes 
nicely the dissolution profiles of ibuprofen and indomethacin regardless the shaking 
speeds in question. At the moment the method is useful for the classification of dissolution 
rates because of rather long centrifugation times before the sampling. By shortening the 
centrifugation time, more detailed dissolution studies are possible for more rapidly 
dissolving materials. 
 
 
 
Figure 6 Aqueous dissolution profiles of ibuprofen and indomethacin at different shaking 
speeds (300, 600 and 1200 rpm) (n=3). Modified from paper IV. 
5.1.4 Scaling down the dissolution testings (I, II, III, IV) 
The scaling down of the dissolution testing from the traditional basket method (e.g. USP, 
2009; Ph. Eur., 2009) via micro dissolution method to the 96-well plates was successful. 
Main focus in the dissolution testing has been in the quality control and the several stages 
of drug development (FDA, 1997a). The large amount of drug compound needed has often 
limited the use of dissolution testing at the drug discovery stage, which the new methods 
now enable.    
Alongside with the regulatory dissolution methods, the small scale dissolution methods 
can be used to study the results, e.g., at the initial states (0-5 min) of the dissolution 
process. Dissolution profiles from the early stage of drug discovery process can be used to 
improve the knowledge on lead candidates. Further, while more complicated, hard to get 
and expensive media, e.g. HIF, can be utilized with these small scale methods, if needed.    
C
on
ce
nt
ra
tio
n 
(m
g/
m
l) 
 
 
 
 
42
5.2 Solubility screening 
5.2.1 HTS 96-well plate methods (III, IV) 
Both kinetic (III) and equilibrium (IV) 96-well plate methods were developed in this thesis 
work. The fact that amphiphilic compounds decrease the surface tension (γ) of water 
linearly within a concentration range limited by air/water partitioning at the lower 
concentration end, and solubility/critical micelle concentration (CMC) at the higher end, 
was utilized in the development of the kinetic method. The solubility value can be 
determined from these isotherms, if the compound is more likely to precipitate than to 
form micelles. The phenomenon is described by the classical Gibbs adsorption isotherm: 
 
cRT ln
1
∂
∂
−=Γ γ      (8)
       
where Γ is surface excess, R is gas constant, T is temperature and c is concentration.  
The measured Gibbs isotherm for ibuprofen is shown in Figure 7. The solubility of 
ibuprofen can be obtained from the focal point between the sloping part and the level part 
of the isotherm. After this point, solid and solvated phases are in equilibrium and the 
amount of the free compound is constant in the solution. At higher concentrations, all 
material exceeding the solubility limit will be in the solid phase, which has no effect on 
the surface tension. Figure 7 also shows the effect of pH on the isotherm of ibuprofen. The 
solubility of ibuprofen is lower at pH 1.2 (0.19 mg/ml) than in pure water (0.23 mg/ml). 
This is seen from the shift of the adsorption curve. 
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Figure 7 Gibbs isotherm for ibuprofen in aqueous solution. Surface tension is reduced with 
increasing ibuprofen concentration until a solubility limit is reached. By lowering the 
pH decreases the solubility of ibuprofen, which is seen from the transition point at 
lower concentration (n=12, methanol was used as a presolvent). Modified from paper 
III.   
The slope of the linear part just before the transition point is inversely proportional to the 
cross-sectional area of the compound at the interface (Suomalainen et al., 2004) (Figure 
7). With ibuprofen the molecular area differed between the two pHs; the absolute value of 
the slope for ibuprofen at pH 6.8 was 43.0 corresponding the cross-sectional area per 
molecule 0.0096 Å2, compared to the absolute value of the slope (17.9) and cross-sectional 
area (0.023 Å2) at pH 1.2. With indomethacin the slopes and cross-sectional areas were 
similar in both media. These differencies may be due to the different interactions between 
solvent and solute molecule.      
A linear dependency was found between the solubilities in the microtensiometer and 
shake-flask measurements for ibuprofen (Figure 8). Best fit of the linear curve gave a 
slope of 1.16 with an intercept at around 180 μg/ml. Differences in the solubility between 
the samples were clearly detected, and the correlation was at a reasonably good level for 
fast screening purposes and, thus, clear distinction between low and high solubility 
environments is possible. The indomethacin results did not fall on the same fitted line as 
the ibuprofen results, which is likely due to the differences in the precipitation rates of the 
two compounds. Still, also with indomethacin it was possible to distinguish between the 
high and low solubility conditions. Not at all unexpectedly, for both the model compounds 
the solubilities measured by the surface tension method were consistently higher than 
those from the (equilibrium) shake-flask method − due to the co-solvent effect (Fligge and 
Schuler, 2006). This is common feature to all HTS kinetic methods (Pan et al., 2001; Chen 
et al., 2002b; Bard et al., 2008) (Figures 8 and 9). 
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Figure 8 Measured ibuprofen solubilities with the novel surface tension method (y-axis) as a 
function of the solubilities from the shake-flask measurements (x-axis). Modified from 
paper III.  
Several variables were tested in order to study the effects of different solvent systems on 
the reliability and applicability of the microtensiometry measurements. Studied media 
environments included, e.g., electrolytes, and surfactants. NaCl and CaCl2 (0.9% and 2%) 
had only limited effects on the solubility of ibuprofen. Surfactants, sodium dodecyl 
sulphate (SDS) and Tween 80, increased the solubility slightly below their CMC values, 
but the increase was much more evident above the CMC values. The pH effect on the 
acidic model compounds was as expected; the higher the pH, the higher the solubility. 
Most importantly, the presence of other materials in the medium did not disturb the 
determinations.  
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Figure 9 Drug solubilities by the surface tension (black, n=8-12) and shake-flask (grey, n=2) 
measurements; effect of the dissolution media. Modified from paper III. 
Most of the HTS methods measure the kinetic solubility when the lead compound is at 
dissolved state in the beginning of the measurement and the co-solvent(s) may 
overestimate the solubility (Chen et al., 2002b). The HTS equilibrium solubility method 
was developed to avoid that, so in the starting point the compound was in the solid form. 
The results from the equilibrium 96-well plate correlated well (R2=0.931) with the values 
from the shake-flask method over five orders of magnitude in aqueous solubility with 
twenty model drugs (Figure 10) (IV). The relative deviation of the 96-well plate results 
was always less than 7-fold. Relative overestimation by the 96-well plate method was the 
most significant for compounds with solubility values lower than 10 μg/ml (circled area in 
Figure 10). Still, the 96-well plate method gave reliable solubility profiling: 98% of the 
tests were within the predictive confidence intervals of 95%. 
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Figure 10 The solubilities from shake-flask (y-axis) and equilibrium HTS methods (x-axis). 
Modified from paper IV.   
Despite the medium, the methods gave similar values. Even 10.000-fold changes in 
solubility were detected depending on the medium, but the correlation between the 
equilibrium HTS and shake-flask methods remained good. For example, the solubility of 
diclofenac sodium at pH 1.2 was 0.002 mg/ml and at pH 6.8 15.3 mg/ml using the HTS 
method; the corresponding values obtained by the shake-flask method were 0.003 mg/ml 
and 24.0 mg/ml, respectively. The solubilities were determined accurately over a wide 
solubility scale (0.002–169.2 mg/ml), which is a true advantage of the 96-well plate 
method. Compounds with vastly different solubilities can be determined with the method 
at small drug quantities and utilize method in the early drug discovery stage when only 
small quantities of compounds are available. Equilibrium 96-well plate method from 
Alelyunas et al. (2009) included HPLC, which might slow down the process and, 
traditionally, the equilibrium solubility has not been measured until the early phase of 
drug development stage (Lipinski, 2003).    
Also the kinetic HTS method (microtensiometry) is suitable for drug solubility 
screening purposes at the drug discovery stage. Although the method has few limitations, 
e.g. it might be difficult to distinguish between the precipitation and micelle formation 
behavior or some very soluble compounds might not sufficiently partition to the water/air 
interface, it has several benefits compared to other kinetic HTS methods. The method does 
not require standard curves or filtrations, solid residues do not disturb the determinations, 
large concentration scales are measurable and low UV absorption of poorly soluble drugs 
does not matter (Bevan and Lloyd, 2000; Pan et al., 2001). It can be stated that the method 
is very well utilizable for poorly soluble drugs, which partition sufficiently to the water/air 
interface. Kinetic HTS method was also used to measure the solubility of ibuprofen as a 
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function of time. Samples were remeasured after 5 hours, in which time the solubility 
values did not change too much indicating that overestimation was more due to the co-
solvent effect than supersaturation. The dissolution of ibuprofen was fast and the 
dissolution profile as a function of time just ascertained that dissolution had taken place. It 
is compound specific, how fast the dissolution takes place and the equilibrium solubility is 
reached.     
Further, ibuprofen and indomethacin results from both the 96-well plate methods were 
compared to each other at aqueous media pH 1.2 and 6.8. In both cases the 96-well plate 
methods gave maximum 7-fold higher solubility values compared to the shake-flask 
method. Only when using ethanol or methanol as presolvents the kinetic solubility values 
were more than 7-fold higher than the shake-flask solubility values (Figure 8). The 
overestimation by the HTS 96-well plate methods compared to the shake-flask method 
could be due to the different scales more than due to the partitioning during the kinetic and 
equilibrium solubility testings.      
5.2.2 Polymorphic changes (IV) 
During the shake-flask solubility tests, changes in the solid-state form of piroxicam were 
recognized; the solubility of piroxicam was first increased in the aqueous solutions, after 
which it was decreased to the equilibrium level. Also the color of the solid residue was 
changed during the test from white (anhydrate) to yellow (monohydrate) indicating the 
change in the physical state of the material. The changes were confirmed by XRPD and 
DSC techniques. Piroxicam raw material contains α- and β-forms (both anhydrates), but 
crystalline solid residues of piroxicam monohydrate and β-form (anhydrate) were formed 
in the solubility test at 5h time-point (Kojic-Prodic et al., 1982; Bordner, 1984; Vrecer et 
al., 2003) (Figure 11). For the other model compounds, no polymorphic changes were 
noticed during the shake-flask determinations.   
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Figure 11 XRPD diffraction patterns of piroxicam in the shake-flask measurements. The 
diffractograms represent the solid residue recrystallized from methanol (starting 
material in HTS), raw material (starting material in shake-flask), pure piroxicam 
monohydrate and anhydrated α- and β-forms.  
In the equilibrium HTS method (pseudo)polymorphic changes occurred with four model 
drugs; piroxicam, indomethacin, diclofenac sodium and spironolactone (Table 11) (Figure 
11). From XRPD and DSC results it was obvious that the starting materials in the shake-
flask and HTS methods were not of the same form. Also spironolactone is known to 
crystallize from different solvents (e.g. methanol, acetonitrile, ethanol, ethyl acetate and 
benzene) in different polymorphic forms (El-dalsh et al., 1983; Beckstead et al., 1993). 
During the HTS solubility tests no polymorphic changes were, however, observed. 
Although some materials had (pseudo)polymorphic changes during the solubility testing, 
these changes were not problematic for the interpretation of the results, because both the 
shake-flask and 96-well plate methods do measure the equilibrium solubility and the 
possible transformations are easily observed. Still, possible polymorphic changes of drug 
candidates may have an influence on the solubility results in solubility screening and, later 
on, on the drug development (Bauer et al., 2001).  
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Table 11. Starting and raw material results from the XRPD (polymorphic form) and DSC 
(melting temperatures) measurements (n=3). Modified from paper IV. 
Compound XRPD DSC Reported melting 
temperature 
Diclofenac sodium 
raw material (Shake-flask) 
starting material (HTS) 
 
I, III 
II, III 
 
288.3oC 
285.5oC 
 
II=180.5oCa 
 
Indomethacin 
raw material (Shake-flask) 
starting material (HTS) 
 
 
γ 
α, γ 
 
 
160.0oC 
154.0oC, 160.5oC 
 
 
γ=160-161oCb 
α=152-154oCb 
 
Piroxicam 
raw material (Shake-flask) 
starting material (HTS) 
 
α, β  
monohydrate 
 
202.4oC 
201.5oC 
 
α=202.6oCc 
β=199.7oCc 
monohydr.=202.0oCc 
aLlinas et al., 2007; bChen et al., 2002a; cVrecer et al., 2003 
5.3 Human intestinal fluid (HIF) 
5.3.1 Characterization of fasted state HIF (IV) 
HIF was collected from five healthy volunteers’ duodenum. Inter- and intraindividual 
variations were observed in the study (Tables 12 and 13), like in the earlier studies 
(Lindahl et al., 1997; Clarysse et al., 2009b). The mean pH value measured from the 
pooled HIF was 6.24 compared to values from 6.6 to 7.5 and the mean osmolality was 205 
mOsmkg-1 compared to values of 200–271 mOsmkg-1 (Table 6).  
The mean of the total bile salt concentration in fasted HIF was 3.63 mM, which is in 
line with the earlier literature values from 2.0 to 3.5 mM (Table 6). Instead, the 
phospholipid concentration (1.8 mM, median 1.1 mM) was higher than in the earlier 
studies (0.2–0.6 mM) (Table 6) because of one sample, which was very concentrated. The 
samples vary between individuals and individual concentrations of up to 2.7 mM have 
been found in fasted upper small intestine earlier (Clarysse et al., 2009b). The mean 
cholesterol level of HIF was 1.8 mM, which was close to the level found by Mansbach et 
al. (1975) (1.5 mM).  
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Table 12. Summary of volunteers’ (V1-5) characteristics and human intestinal fluid 
collection from duodenum.  
Volunteer Gender Age BMI 
(kg/m2) 
Volume 
(ml)  
pH Osmolality 
(mOsm/kg) 
V1 Male 25 21.7 70 6.62 176 
V2 Female 39 20.8 100 5.19 219 
V3 Male 37 23.1 100 6.60 209 
V4 Female 24 21.6 40 6.27 213 
V5 Female 31 20.9 35 6.51 207 
Mean 
±s.d. 
- 29 
8 
21.6 
0.9 
69 
31 
6.24 
0.60 
205 
17 
Table 13. Composition of fasted HIF from five healthy volunteers (V1-5). In the table   
DC=deoxycholate, C=cholate, CDC=chenodeoxycholate and 
UDC=ursodeoxycholate 
  
Bile  
salts (mM) 
 
 
Phospho-
lipids 
(mM) 
 
 
Cholesterol 
(mM) 
 
 
 
DC 
(%) 
 
C 
(%) 
 
CDC 
(%) 
 
 
 
UDC 
(%) 
 
V1 2.45 1.35 1.48 29.5 42.5 23.8 4.2 
V2 2.62 1.11 1.68 24.6 56.7 18.1 0.6 
V3 4.54 2.18 2.27 3.4 64.6 25.3 6.7 
V4 1.65 0.99 1.71 0.8 57.7 35.4 6.1 
V5 8.60 4.69 1.48 7.1 66.6 25.6 0.7 
5.3.2 HIF in solubility testing (IV) 
Equilibrium HTS solubility tests were performed using the fasted state HIF (pH 6.24) for 
13 model drugs and the results were compared to the HTS solubility results in the aqueous 
buffer solution at pH 6.8 (Figure 12) – resulting in a fair correlation (R2=0.630). More 
importantly, the absolute values of compound solubility differed only modestly (less than 
6.9-fold in all cases), even though 1000-fold range of solubilities were studied. Slightly 
increased solubility values in HIF compared to the buffer solution pH 6.8 were seen for 
piroxicam, naproxen, rifampicin and diclofenac sodium. Vice versa, the solubilities in HIF 
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compared to pH 6.8 buffer solution were decreased for ibuprofen and ketoprofen. No 
major differences were seen between the solubility in buffer solution pH 6.8 and HIF 
suggesting that buffer is an adequate medium when studying dissolution and solubility 
with compounds in the 100 μg/ml–100mg/ml solubility range. However, we can not rule 
out the possibility that more significant solubility differences would be seen for the 
compounds with solubility below 100 μg/ml. For example, preliminary solubility test of 
beclomethasone dipropionate, showed 150 times higher solubility in HIF (0.6 μg/ml) than 
in the buffer at pH 6.8 (0.004 μg/ml). Obviously, more detailed studies are needed to 
determine the limits and utilization potential of HIF in drug solubility and dissolution 
testing, especially in the case of the compounds with very low solubility. It is worth 
noting, however, that the simple buffer is useful medium over surprisingly wide solubility 
range that extends at least to 102 μg/ml. 
HIF was, found to be a suitable solubility/dissolution medium for the 96-well plate 
testings. The small volumes make it possible to utilize the HIF also as a medium in drug 
discovery process, which may have an even more pronounced importance for very low 
solubility compounds. HIF is the most relevant solubility medium, and in this system it 
can be used instead of the buffers or simulated intestinal fluids, if needed. 
 
 
 
 
Figure 12 The solubilities in HIF (y-axis) and buffer solution pH 6.8 (x-axis). Modified from 
paper IV. 
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6 Conclusions 
The main conclusions drawn based on the results of this study are: 
 
1.  Channel flow method was introduced to the dissolution testing. The method is 
applicable on drug dissolution testing and enables especially kinetic follow-up 
at the very beginning of the dissolution process. The results from the channel 
flow method and the intrinsic dissolution method correlated well with each 
other. Later the channel flow method has been further developed to study the 
solvent-mediated solid-state transformation during dissolution (Aaltonen et al., 
2006; Lehto et al., 2008).  
 
2.  A micro dissolution method was used to determine equilibrium solubilities of 
model compounds with smaller volumes than by the shake-flask method. The 
solubility results from the micro dissolution were reliable indicating utilization 
potential of the micro dissolution method instead of shake-flask method. 
Miniaturization was successful to the 96-well plates.   
 
3.  A 96-well plate method was developed for measuring the equilibrium drug 
solubilities and dissolution profiles as a function of time in microlitre scale. 
The method is useful for screening purposes at early stages of drug 
development. Also polymorphic changes of compounds can be studied. The 
methodology developed is the first true equilibrium solubility measuring HTS 
system utilizing 96-well plates, meaning that in the beginning the compound 
was in solid form.   
 
4.  A novel surface tension based microtensiometric method was presented for 
kinetic HTS of drug solubility properties. The method was tested by 
determining physiologically relevant parameters on the solubility of model 
compounds. The method is well suited for classifying purposes and solubility 
screening tests. 
 
5.  HIF from duodenum was used as a medium for the first time in 96-well plate 
equilibrium solubility testings. Microliter volumes make it possible to utilize 
HIF, the most relevant solubility medium, in dissolution testing at drug 
discovery stage. This may be even more important in the future with very low 
solubility compounds. Still, the aqueous buffer solutions are the first choice 
due to good prediction capacity, low costs, ease of access and good correlation 
with model drugs.   
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